VOLTAREN OPH SOLN Rx
Generic Name and Formulations:
Diclofenac sodium 0.1%.
Indications for VOLTAREN OPH SOLN:
Post-op inflammation after cataract extraction. Photophobia and pain in corneal refractive surgery.
Cataract surgery: 1 drop 4 times daily beginning 24 hrs post-op for 2 weeks. Corneal refractive surgery: 1–2 drops within the hour prior to surgery, then within 15 minutes post-op, then 4 times daily for up to 3 days.
Bleeding tendencies. Complicated or repeat ocular surguries. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. May delay wound healing. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Should not be used by patients currently wearing soft contact lenses. Monitor refractive stability for 1 year. Pregnancy (Cat.C); avoid during late pregnancy. Nursing mothers: not recommended.
Caution with medications that prolong bleeding time. Concomitant use of topical steroids may increase potential for healing problems.
Burning, stinging, dry eye, other ocular effects, increased bleeding (including hyphemas).
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|